Axsome Therapeutics (AXSM) net assets (shareholders' equity)

Net assets · fiscal 2025
$88.30M

Axsome Therapeutics (AXSM) had net assets of $88.30M at the end of fiscal 2025 (December 31, 2025). That is 54.9% higher than the $57.02M of fiscal 2024. Figures as of 19 Nov 2026, 00:32 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$88.30M
Change on fiscal 2024
+54.9%
Growth, 5 years
−4.9% a year
Growth, 10 years
+6.6% a year
Highest on record
$190.98Mfiscal 2023
Lowest on record
-$3.20Mfiscal 2014
Fiscal years on record
122014–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Axsome Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets shrank at a compound 4.9% a year; over ten years the rate was 6.6% a year. Across the 12 fiscal years on record (2014–2025), the highest was $190.98M in fiscal 2023 and the lowest -$3.20M in fiscal 2014.

History · 12 fiscal years

Net assets by fiscal year

Axsome Therapeutics net assets (shareholders' equity), year by year

Axsome Therapeutics (AXSM) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$88.30M 54.9% up
2024$57.02M 70.1% down
2023$190.98M 74.3% up
2022$109.56M 600.9% up
2021$15.63M 86.3% down
2020$113.79M 36.3% down
2019$178.72M 18,955.2% up
2018$937.92K 94.4% down
2017$16.72M 22.5% down
2016$21.57M 53.6% down
2015$46.44M—
2014-$3.20M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Axsome Therapeutics and comparable companies
CompanyNet assetsFiscal year
Immunovant IMVT$852.59M2026
Axsome Therapeutics AXSM$88.30M2025
Chemed CHE$979.41M2025
Oruka Therapeutics ORKA$471.93M2025
Arrowhead Pharmaceuticals ARWR$50.31M2026
MSA Safety MSA$1.37B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AXSM

Axsome Therapeutics, figure by figure

Axsome Therapeutics (AXSM) overview: price, valuation and scorecardAll health care companies by market value

Axsome Therapeutics net assets (shareholders' equity): questions and answers

What are Axsome Therapeutics's net assets?

Axsome Therapeutics (AXSM) had net assets of $88.30M at the end of fiscal 2025 (December 31, 2025). That is 54.9% higher than the $57.02M of fiscal 2024.

What is the growth rate of Axsome Therapeutics's net assets?

Over the five fiscal years to 2025 net assets shrank at a compound 4.9% a year; over ten years the rate was 6.6% a year.

What are the highest and lowest net assets figures on record for Axsome Therapeutics?

Across the 12 fiscal years on record (2014–2025), the highest was $190.98M in fiscal 2023 and the lowest -$3.20M in fiscal 2014.

How is Axsome Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Axsome Therapeutics it is on record here for 12 fiscal years, 2014 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Axsome Therapeutics (AXSM) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/AXSM/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.